reports have emphasised the severity of neurological and systemic disorder in patients with toxocaral meningoencephalitis.1 2 " Apart from neck stiffness our patient was surprisingly well with no evidence of encephalitis. Her diagnosis might have been that of an atypical viral meningitis had Romanovsky staining not been performed. We think that this investigation may be useful in culture negative meningitis when there are no signs of viral infection.
Toxocara enzyme linked immunosorbent assay titres using T canis excretory-secretory products as antigen Acute We have shown that exocrine pancreatic deficit is common in diabetes and that the degree of this deficit parallels the endocrine deficit.1-4 From necropsy data we also know that the size of the pancreas in patients with insulin dependent diabetes is smaller than in normal people.5 In order to confirm this observation in insulin dependent diabetes5 and to determine whether pancreatic size is also altered in non-insulin dependent diabetes mellitus we studied the pancreatic size in patients with diabetes mellitus using ultrasound techniques.
Patients, methods, and results
Sixty adult diabetic patients were investigated: 22 had insulin dependent diabetes (group 1) and 19 non-insulin dependent diabetes (group 2) and 19 were non-ketotic patients who had to be given insulin because of inadequacy of diabetic control with oral hypoglycaemic agents (group 3). Nineteen healthy controls were also studied.
All scans were performed by one of us (LAB), using a real time linear array system (Picker LS 3000).
The patients and controls were scanned in the morning after an overnight fast. Scans were performed with the patients supine and erect. A more complete and clearer visualisation of the pancreas was achieved by scanning with the patient erect. The head (defined as the area medial to the superior mesenteric vein) and the body of the pancreas were measured separately, since these were often visualised to best advantage in different views. As the head is often oriented in the longitudinal plane parallel to the inferior vena cava, measurements were made in this plane below the portal vein as well as in the transverse or oblique plane (taking the midpoint of the confluence of the superior mesenteric and splenic veins as the marker point).
In normal subjects the longitudinal section of the head was frequently larger than the transverse sections. This did not occur in any of the diabetic patients. The tail of the pancreas was well seen as it passed anterior to the left kidney, but the more distal portion extending into the splenic hilum (which represents a very small part of the pancreatic mass) was rarely seen.
The scans were recorded on photographic paper. The outline of the pancreas was mapped out and the areas computed using a Numonics Graphic Analyzer (Numonics, Japan).
Both the head and the body of the pancreas in patients of group 1 and 2 were noticeably smaller than in the controls (table) . The head and body of the pancreas in patients of group 2 were significantly larger than in group 1. Pancreatic enzyme values at the time of clinical onset of insulin dependent diabetes mellitus indicate that in these patients exocrine pancreatic reserve may be diminished at the time of presentation, suggesting that exocrine damage occurs not as a long term complication of and sequel to diabetes but probably as a consequence of the process which caused the pancreatic islet and 3 cell damage. 4 The factors responsible for the shrinkage of pancreas through a reduction of exocrine tissue may be immunological (lymphocytic infiltration has been observed); genetic; subclinical viral pancreatitis; or lack of trophic effect of insulin on exocrine pancreas. The last is particularly relevant to non-insulin dependent diabetes. a Atrial natriuretic peptide concentrations in plasma of children with congenital heart and pulmonary diseases Three peptides have recently been isolated from mammalian atrial myocytes, all of which have natriuretic, diuretic, and hypotensive activity. In man the smallest of these, a human atrial natriuretic peptide, comprises 28 amino acids.'
Studies in animals suggest that the peptides are released from the atria in response to increased atrial pressure.2 A similar mechanism might play a part in controlling the release of a human atrial natriuretic peptide from the human heart. To test this hypothesis we measured the plasma concentrations of a human atrial natriuretic peptide in children with various types of congenital heart disease and bronchopulmonary dysplasia, which are known to be associated with high atrial pressure and atrial stretching.
Four children with bronchopulmonary dysplasia, Northway stage IV,' aged 17-27 months and 10 children with congenital heart diseases aged 1 month to 15 years were studied. The mean gestational age and birth weight of the children with bronchopulmonary disease was 32 weeks and 1580 g, respectively. Among the patients with cardiac disease there were three cases of Fallot's tetralogy (one after surgical reconstruction) and one each of patent ductus arteriosus, transposition of the great arteries, ventricular septal defect, and coarctation of the aorta, tricuspid atresia, ventricular septal defect, mitral stenosis, and cardiomyopathy. All diagnoses were made on the basis of x ray findings, two dimensional echocardiography, or cardiac catheterisation. None of the children had a history of any other disease known to affect water balance. The patients with bronchopulmonary dysplasia were treated with diuretics and digoxin. Four children with congenital heart disease were treated with digoxin and frusemide. The control group consisted of 51 children (24 boys, 27 girls) who had been admitted to hospital aged 1 month to 16 years with endocrine disorders such as delayed puberty, retardation of growth, and obesity or who were recovering from infectious diseases or minor surgery. Children suffering from cardiac and bronchopulmonary diseases and those with disorders affecting the fluid and electrolyte balance were excluded.
Blood samples were taken for measurement of a human atrial natriuretic peptide concentrations from peripheral veins during routine sampling between 8 am and 11 am with patients supine. Concentrations of a human atrial natriuretic peptide were measured by radioimmunoassay as described above. 3 The mean concentration of a human atrial natriuretic peptide in the control group was 27 fmol/ml (range 1-45-5 fmol/ml (3-136-5 pg/ml)) (figure). The mean plasma concentration in children under 1 year of age did not differ significantly from that of children older than 1. By contrast, concentrations up to 10 times higher were found in the group of children with congenital heart or bronchopulnonary diseases. An overlap with the upper range of the concentrations of a human atrial natriuretic peptide in the control group was observed in the one patient who had undergone surgical reconstruction of Fallot's tetralogy.
Comment
It has recently been reported that a human atrial natriuretic peptide, when given as an intravenous bolus to healthy subjects, increased urinary sodium excretion and urine volume and immediately decreased blood pressure, probably owing to vasodilatation.4 ' This observation together with the fact that a human atrial natriuretic peptide is a hormone circulating in the blood implies that the cardiac atria are one site where the volume ofvascular fluid is regulated. The our study may be sufficiently high to elicit cardiovascular and renal effects. This is supported by Tikkanen et al, who reported that during infusions of a human atrial natriuretic peptide plasma concentrations above 33 fmol/ml (100 pg/ml) were associated with a slight decrease in blood pressure and a definite natriuresis and diuresis.5 The same authors showed that plasma ct atrial human natriuretic peptide concentration was raised in patients with congestive heart failure.5 This observation together with our finding of raised concentrations in children with cardiopulmonary disease are consistent with the idea that increased preload resulting in atrial stretch stimulates the release of a human atrial natriuretic peptide into the circulation. Moreover, the data suggest that the hormone might be valuable as a non-invasive humoral marker in the diagnosis of various cardiac and pulmonary diseases and in evaluating responses to treatment.
